Group One Trading’s Phathom Pharmaceuticals PHAT Stock Holding History

Group One Trading’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$70.9K	Sell	9,708 -4,173	-30%	-$39.3K	﹤0.01%	4994
2026 Q2	$151K	Sell	13,881 -3,058	-18%	-$34.9K	﹤0.01%	4522
2026 Q1	$188K	Sell	16,939 -86,745	-84%	-$1.1M	﹤0.01%	4157
2025 Q4	$1.72M	Buy	103,684 +99,436	+2,341%	+$1.42M	﹤0.01%	2406
2025 Q3	$50K	Buy	+4,248	New	+$43.8K	﹤0.01%	5964
2025 Q2	–	Sell	-2,404	Closed	-$13.3K	–	8491
2025 Q1	$15.1K	Buy	+2,404	New	+$14.6K	﹤0.01%	6004
2024 Q4	–	Sell	-15,130	Closed	-$187K	–	7804
2024 Q3	$274K	Buy	15,130 +7,762	+105%	+$108K	﹤0.01%	3345
2024 Q2	$75.9K	Buy	+7,368	New	+$75.9K	﹤0.01%	4180
2024 Q1	–	Sell	-1,545	Closed	-$13.1K	–	7755
2023 Q4	$14.1K	Buy	+1,545	New	+$13.3K	﹤0.01%	5980

Other funds holding PHAT

Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Catalys Pacific Tokyo, Japan $210M AUM 33.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Group One Trading's PHAT Position: Q3 2026 in Review

Group One Trading reduced its Phathom Pharmaceuticals (PHAT) stake by 30% in Q3 2026, selling an estimated $39.3K and leaving 9,708 shares worth $70.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4994.

Group One Trading first reported a position in PHAT in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.72M in Q4 2025. 61 funds tracked by Wall St. Rank hold PHAT as of Q3 2026.

Group One Trading held 9,708 shares of Phathom Pharmaceuticals worth $70.9K as of Q3 2026.
Group One Trading sold 4,173 Phathom Pharmaceuticals shares in Q3 2026, an estimated $39.3K.
Phathom Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q3 2026, its #4994 holding.
Group One Trading first reported a position in Phathom Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
Group One Trading's Phathom Pharmaceuticals position peaked at $1.72M in Q4 2025.
61 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q3 2026.

Based on Group One Trading's 13F filing for Q3 2026, filed 10 Nov 2026.